Nuclear factor-kappaB in development, prevention, and therapy of cancer.
about
Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatmentThe zinc finger protein ZNF268 is overexpressed in human cervical cancer and contributes to tumorigenesis via enhancing NF-κB signalingSquamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterizationNeem components as potential agents for cancer prevention and treatmentTranscription Factors in the Cellular Response to Charged Particle ExposureGemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cellsCytokines as biomarkers of nanoparticle immunotoxicityNorisoboldine suppresses VEGF-induced endothelial cell migration via the cAMP-PKA-NF-κB/Notch1 pathwayAberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapyModulation of NF-κB signalling by microbial pathogensDynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells.Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataStimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinomaSelection and characterization of anti-NF-kappaB p65 RNA aptamers.Targeting the UPS as therapy in multiple myeloma.Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.Therapeutic strategies for inhibiting invasion in glioblastoma.Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy20-Hydroxycholecalciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-kappaB activity by increasing IkappaB alpha levels in human keratinocytes.Characterization of anti-NF-kappaB RNA aptamer-binding specificity in vitro and in the yeast three-hybrid system.Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells.RelB/NF-κB2 regulates corticotropin-releasing hormone in the human placenta.Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase.Anti-Inflammatory Agents for Cancer Therapy.Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinomaCK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo.Emergence of protein kinase CK2 as a key target in cancer therapyER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsWithanolides-induced breast cancer cell death is correlated with their ability to inhibit heat protein 90Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFκB pathwayShRNA-targeted COMMD7 suppresses hepatocellular carcinoma growth.Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells.A novel DC therapy with manipulation of MKK6 gene on nickel allergy in miceSignaling Networks of Activated Oncogenic and Altered Tumor Suppressor Genes in Head and Neck Cancer.Moringa Oleifera aqueous leaf extract down-regulates nuclear factor-kappaB and increases cytotoxic effect of chemotherapy in pancreatic cancer cells.Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation.Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy
P2860
Q21328704-E2E67109-B0FD-44C9-8FF8-97437C31D570Q24301538-16B23CCF-8C90-404A-8EDE-AF22B9CC7FD1Q26765060-2DB78416-9B2D-4DE3-B101-4C6F6D676AE9Q26995699-EA2909CD-3ABB-442F-8F90-A16EA7BC2547Q28069717-E3BDDAD1-EEC2-4EF5-871F-373010C7DBF0Q28297927-C723B859-8B93-4A6C-93B0-D7675872444BQ28383550-28C8C4B8-E269-4565-8A7A-4B3991F500FEQ28536541-27522742-E358-4A1E-B093-1077A380A1CCQ28542664-1ABE15C6-E4DC-44BD-9424-71CBC5FFD8D8Q28709497-18648CDA-7B28-422C-856F-1CC84169BED5Q30489022-E6EB1DE7-FABE-4A22-AE48-99E221BFB5E3Q30936712-5A3F173F-9D05-48B8-85F0-949A6947DFC0Q33317415-19649A7D-43F8-4BF8-9222-CB80EF750514Q33329753-682FA5D1-2638-487C-A2E3-18E6E326AFA1Q33384287-8C1D4740-025D-43BE-9BD2-DD42D8DB6434Q33405119-479A8D9C-3DA3-45B9-B145-F17890B67FFEQ33426563-3FDEB34E-5659-435C-897A-CFE54E0ACDA2Q33437264-1C73BED0-62FC-4AF7-B4B4-5D495EB2670BQ33471485-B95C1246-F5BB-4C62-AEEE-AD212DEFE8C8Q33495466-4B1BD594-E833-47BA-A60C-32C531AC379AQ33609716-D26E8E1B-1490-4B81-BB63-372E673A6BECQ33636373-BDBEB9BE-1AEE-4E6E-B863-1741A060CDBAQ33648301-B1C875C9-42DA-4AA6-B280-62D3DCD589AEQ33744129-707BDB2D-B7DD-422E-B59A-56B346FBCADAQ33751186-9C9F74E7-08CA-4580-BEFD-26527D7146A9Q33817704-5C648852-6475-4ADA-8783-477D5B8D592CQ33843578-AD1CA8FD-BF14-4866-A471-5A27F8458598Q33872837-9A808A3D-EFDF-4156-8843-FD91BE23C943Q34046848-5AC28E36-78A2-45EA-8A34-A4FC103F8AA8Q34168267-CBE80199-6372-4413-B088-21F9674A5D36Q34218976-BB907EC1-A72B-4AEE-BDFA-D8DB33E5C128Q34305025-D84272F5-D84E-4A80-9164-8D530DFC52AEQ34415256-B2AAF6D5-44D7-4342-936F-E8433253F1D7Q34438128-58E71E29-04CA-4BF4-846D-569E2BC351A0Q34520431-E8202D3B-A758-47C7-A4F6-1D1FB79933D9Q34841315-7FEAA01D-27D0-4481-BA79-F0940A8B5E62Q34902060-31BF692A-14B5-4777-8A52-D9498D438F0CQ34956273-DCC115E3-2F0B-48C7-96E8-3CFAFD43B956Q35065451-E67E109C-3487-418B-BA98-DF455BDC4538Q35118157-7BDBFA1C-FB1A-4177-A604-C55FA3BCE1E4
P2860
Nuclear factor-kappaB in development, prevention, and therapy of cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Nuclear factor-kappaB in development, prevention, and therapy of cancer.
@ast
Nuclear factor-kappaB in development, prevention, and therapy of cancer.
@en
type
label
Nuclear factor-kappaB in development, prevention, and therapy of cancer.
@ast
Nuclear factor-kappaB in development, prevention, and therapy of cancer.
@en
prefLabel
Nuclear factor-kappaB in development, prevention, and therapy of cancer.
@ast
Nuclear factor-kappaB in development, prevention, and therapy of cancer.
@en
P1476
Nuclear factor-kappaB in development, prevention, and therapy of cancer.
@en
P2093
Carter Van Waes
P304
P356
10.1158/1078-0432.CCR-06-2221
P407
P577
2007-02-01T00:00:00Z